Abstract
Overview
Introduction
The restrictive, highly competitive antidyslipidemic market is going to become
even further genericized, which will add to the challenges that drug makers
are facing. Despite over 300m people being eligible for antidyslipidemic
treatment, there is still a lot of under-diagnosis and under-treatment, but it
will be a major issue capturing all the eligible population.
Scope
- Assessment of each of the seven major markets, key drivers for growth and
resistors to growth
- Overview of the main opportunities and threats in each of the seven major
markets
- Forecast analysis including the key events, among them new product
launches, major clinical trials and patent expiries.
- Overview of two case studies (on CETP inhibitors and on the second wave of
patent expiries) including worst and best case scenarios.
Highlights
Despite over 300m people being eligible for treatment in seven major markets,
as well as the recommended treatment goals capturing more patients and
promoting more aggressive therapy, there is a lot of under-diagnosis and
under-treatment. Cost-saving policies further limit the patient potential for
branded agents.
Lowering of LDL-C treatment goals cannot counteract the impact of cost-saving
policies, and does not guarantee a revenue stream for branded agents. This is
why there are currently several outcome trials that regard the potential of
branded agents (Crestor, Vytorin) in new indications/patient groups, e.g.
heart failure and renal disease.
Branded statins' market share is diminishing. Due to the patent expiries of
statins that have taken place in the past five years (especially that of
Zocor) and those going to take place in the near future (especially that of
Lipitor) the branded statins are losing their market share rapidly.
Reasons to Purchase
- Understand key drivers and predict the future performance of key compounds
- Optimize sales and marketing strategy to counter market threats
- Develop commercial strategies across the seven major markets
| 
View Cart
